It is important to note, that for some indications (e.g., Alzheimer’s disease) molecules that induce or potentiate ADAM10 activity are thought to be needed, whereas for the majority of other indications (e.g., cancer, inflammation) the inhibitors of activity are sought after. Here, ADAM10 is linked to early-onset autosomal dominant Alzheimer disease.